Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Lurasidone medicine composition and preparation method

A technology of lurasidone and a composition is applied in the field of solid pharmaceutical compositions of lurasidone, and can solve the problems such as inability to obtain sufficient immediate release properties and the like

Inactive Publication Date: 2012-09-26
李兴惠
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But, because lurasidone is a poorly soluble drug, it cannot obtain sufficient immediate release under many prescription preparation conditions, so there is a report of making it into a preparation containing pregelatinized starch (CN101184489A)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lurasidone medicine composition and preparation method
  • Lurasidone medicine composition and preparation method
  • Lurasidone medicine composition and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-3

[0058] Example 1-3: Preparation of the tablet of the present invention

[0059] Formula (mg / tablet)

[0060]

[0061] Note: In the above embodiments, the binder and polysorbate are prepared with water to form a solution suitable for the dosage and concentration of the formula. The preparation method of each Example 1-3 was carried out according to the general method a.

Embodiment 4-6

[0062] Example 4-6: Preparation of the tablet of the present invention

[0063] Formula (mg / tablet)

[0064]

[0065] Note: The binders and polysorbates in the above Examples 4-6 were prepared with a 30% ethanol aqueous solution into a solution suitable for the dosage and concentration of the formulation. The preparation method of each Example 4-6 was carried out according to the general method a.

Embodiment 7-9

[0066] Examples 7-9: Preparation of tablets of the invention

[0067] Formula (mg / tablet)

[0068]

[0069]

[0070] Note: In the above embodiments, the binder and polysorbate are prepared with water to form a solution suitable for the dosage and concentration of the formula. The preparation method of each Example 7-9 was carried out according to the general method b.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a lurasidone medicine composition and a preparation method. The lurasidone medicine composition comprises the lurasidone shown in the formula (I), sugar alcohol, disintegrant, adhesive, surfactant and optional water-insoluble filler. In the lurasidone medicine composition disclosed by the invention, the contact angle between the surface and water is not greater than 95 degrees. The preparation of lurasidone (particularly tablet) has good release performance and mechanical performance.

Description

Technical field [0001] The invention relates to a solid pharmaceutical composition of lurasidone, in particular to a lurasidone tablet and a preparation method. Background technique [0002] Lurasidone hydrochloride (Lurasidone HCl, in the present invention, the hydrochloride of the substance can be called Lurasidone) is a new type of atypical antipsychotic, October 28, 2010, the U.S. Food and Drug Administration ( FDA) approved it to be marketed under the trade name Latuda for the treatment of schizophrenia. It is a new type of antipsychotic drug with dual effects developed by Japan's Sumitomo Pharmaceutical Company. It has a high affinity for both 5-HT2A receptor and dopamine D2 receptor. It has a significant effect on both the positive and negative symptoms of mental patients. Studies have reported that lurasidone can improve cognitive function. The recommended starting dose is 40mg / d, the effective dose range is 40~120mg / d, and the maximum recommended dose is 80mg / d; Luras...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K9/28A61K9/16A61K9/48A61K31/495A61P25/18
Inventor 李兴惠
Owner 李兴惠
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com